Craft

Abivax

Stock Price

€9.9

2024-10-29

Market Capitalization

€622.9 M

2024-10-29

Abivax Summary

Company Summary

Overview
Abivax is a biotech company that mobilizes the body’s natural immune system to treat patients suffering from inflammatory diseases, infectious diseases, and cancer. It leverages its immune-enhancing and antiviral platforms to optimize and develop drug candidates to treat ulcerative colitis, Crohn’s disease, rheumatoid arthritis, and other inflammatory diseases (ABX464), HIV (ABX464), and liver cancer (ABX196).
Type
Public
Status
Active
Founded
2013
HQ
Paris, FR | view all locations
Website
https://www.abivax.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Didier Blondel

    Didier Blondel, EVP, Chief Financial Officer & Board Secretary

  • Pierre Courteille

    Pierre Courteille, Chief Business Officer

  • Fabio Cataldi

    Fabio Cataldi, Chief Medical Officer

  • David Zhang

    David Zhang, Chief Strategy Officer

Operating MetricsView all

Patents Issued

243
12.0%

FY, 2018

Patent Families

29
11.5%

FY, 2018

Patents Pending

120
9.8%

FY, 2018

LocationsView all

4 locations detected

  • Paris, IDF HQ

    France

    7 Bd Haussmann

  • Waltham, MA

    United States

    880 Winter St #1020

  • Montpellier, Occitanie

    France

    120 Rue Adrien Proby

  • Montpellier, Occitanie

    France

    1919 Route de Mende

Abivax Financials

Summary Financials

Gross profit (FY, 2025)
€4.6M
Net income (FY, 2025)
(€336.1M)
Cash (FY, 2025)
€516.7M
EBIT (FY, 2025)
(€246.1M)
Enterprise value
$108.1M

Footer menu